Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRONARTO: Tiotropium + Olodaterol in COPD Stratified by PIFR
NCT04223843Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tiotropium + Olodaterol with Placebo (2 arms). Primary endpoint: Change From Baseline in Forced Expiratory Volume in One Second Area Under the Curve From 0 to 3 Hours. Started Jan 2020; status: completed.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04223843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223843.